- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07399262
Music-Augmented Rhythmic Gait Training in Multiple Sclerosis
Music-Augmented Versus Non-Music Technology-Based Rhythmic Gait Training in Multiple Sclerosis: A Randomized Controlled Trial of Gait Performance and Clinical Outcomes
Study Overview
Status
Conditions
Detailed Description
Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central nervous system that leads to impairments in motor and cognitive functions, with gait disturbances being among the most common and disabling symptoms. Walking impairments in individuals with MS substantially reduce quality of life and are frequently accompanied by balance deficits, fatigue, and decreased functional capacity, ultimately limiting independence in daily activities.
Recent evidence suggests that rhythmic auditory stimulation and music-based gait training can enhance motor control and walking performance by providing external temporal cues that facilitate movement coordination. In parallel, telerehabilitation has emerged as an effective and accessible rehabilitation approach, enabling supervised exercise delivery while reducing barriers related to transportation, cost, and long-term adherence.
In this randomized controlled trial, a total of 32 individuals with MS who have an Expanded Disability Status Scale (EDSS) score between 0 and 4 and a definite diagnosis according to the McDonald criteria will be recruited. Participants will be randomly allocated into two groups using computer-generated randomization. The intervention group (Group A) will perform rhythmic gait exercises accompanied by music, whereas the control group (Group B) will perform the same exercises without music. Both interventions will be delivered in a telerehabilitation format under the supervision of a physiotherapist.
The intervention program will last four weeks, with training sessions conducted four days per week. Primary and secondary outcome measures assessing walking performance, balance, fatigue, and cognitive function will be administered before and after the intervention period.
The primary objective of this study is to comparatively evaluate the effects of technology-based, music-assisted rhythmic gait training on motor outcomes in individuals with MS and to contribute high-quality scientific evidence to an area that remains underrepresented in the current rehabilitation literature.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Güzin Kaya Aytutuldu
- Phone Number: 05366265884
- Email: guzinkaya14@gmail.com
Study Locations
-
-
Zeytinburnu
-
Istanbul, Zeytinburnu, Turkey (Türkiye), 34015
- Recruiting
- Biruni University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Expanded Disability Status Scale (EDSS) score between 0 and 4.0
Access to the internet via a high-speed smartphone or computer
A score of at least 21 on the Montreal Cognitive Assessment (MoCA)
Functional Ambulation Scale score of Stage 3 or higher
Exclusion Criteria:
- Presence of hearing or visual impairments
Current participation in any structured exercise program
Presence of other neurological, cardiovascular, or orthopedic disorders
History of MS relapse or change in disease-modifying treatment within the last 6 months
Physical conditions preventing safe participation in the exercise program
Comorbid conditions that adversely affect oxygen transport (e.g., severe anemia, peripheral arterial disease)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Rhythmic GaitTraining Group with Music
Participants in this group will perform technology-based rhythmic gait exercises accompanied by music.
The intervention will be delivered via telerehabilitation under the supervision of a physiotherapist, four days per week for four weeks.
|
rticipants will perform standardized breathing exercises and general mobility exercises.
These exercises will be delivered in the same telerehabilitation format and supervised by a physiotherapist.
Participants will perform rhythmic gait training accompanied by music.
The training will be delivered via telerehabilitation with real-time supervision through videoconferencing.
Sessions will be conducted four days per week for four weeks.
Gait training will be guided using instructional videos presented with music accompaniment.
|
|
Active Comparator: Rhythmic Gait Training Without Music
Participants in this group will perform the same technology-based rhythmic gait exercises without music.
The intervention will be delivered via telerehabilitation under the supervision of a physiotherapist, four days per week for four weeks.
|
rticipants will perform standardized breathing exercises and general mobility exercises.
These exercises will be delivered in the same telerehabilitation format and supervised by a physiotherapist.
Participants will perform the same rhythmic gait training program without music.
The training will be delivered via telerehabilitation with real-time supervision through videoconferencing.
Sessions will be conducted four days per week for four weeks.
Gait training will be guided using instructional videos presented without music (silent).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gait Speed
Time Frame: Baseline and immediately after intervention
|
Walking speed is the primary outcome measure of the study and will be assessed using the Timed 25-Foot Walk Test (T25FW).
In this test, participants are instructed to walk a distance of 7.62 m (25 feet) as quickly and safely as possible, without running.
The completion time is recorded in seconds.
Two trials are performed, and the average of the two trials is recorded as the T25FW score.
The T25FW is one of the most well-established and widely used measures for assessing gait impairment and walking speed in individuals with multiple sclerosis
|
Baseline and immediately after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Two Minute Walk Test
Time Frame: Baseline and immediately after intervention
|
The Two-Minute Walk Test (2MWT) will be used to assess functional walking capacity and treatment response.
The total distance walked within two minutes is recorded in meters.
Vital signs are measured before and after the test.
In this study, the 2MWT is preferred over the 6-Minute Walk Test due to its practicality, feasibility, and validated use in individuals with MS without inducing excessive fatigue
|
Baseline and immediately after intervention
|
|
Timed Up and Go Test
Time Frame: Baseline and immediately after intervention
|
In the Timed Up and Go Test, participants are instructed to stand up from a seated position, walk a distance of 3 meters, turn around a reference object, return to the chair, and sit down.
The time required to complete the task is recorded in seconds.
The test is performed three times, and the average time is used for analysis
|
Baseline and immediately after intervention
|
|
Step Length
Time Frame: Baseline and immediately after intervention
|
Kinovea® software (version 0.8.15) is used to perform objective and quantitative kinematic and spatiotemporal gait analysis from video recordings. The software enables the analysis of parameters such as step length, stride length, base of support, step width, cadence, walking speed, and step time (37). In this study, gait will be recorded using a camera positioned in the sagittal plane while participants walk a distance of 3 meters. Colored markers will be placed on the right and left heels to facilitate identification in the video recordings. Several gait cycles will be captured and analyzed independently using Kinovea software to determine step length (distance between consecutive heel strikes of opposite limbs), stride length (distance between consecutive heel strikes of the same limb), cadence (steps per minute), and bilateral step lengths (38-40). Walking speed (V) will be calculated using the formula: |
Baseline and immediately after intervention
|
|
Stride Length
Time Frame: Baseline and immediately after intervention
|
Kinovea® software (version 0.8.15) is used to perform objective and quantitative kinematic and spatiotemporal gait analysis from video recordings. The software enables the analysis of parameters such as step length, stride length, base of support, step width, cadence, walking speed, and step time (37). In this study, gait will be recorded using a camera positioned in the sagittal plane while participants walk a distance of 3 meters. Colored markers will be placed on the right and left heels to facilitate identification in the video recordings. Several gait cycles will be captured and analyzed independently using Kinovea software to determine step length (distance between consecutive heel strikes of opposite limbs), stride length (distance between consecutive heel strikes of the same limb), cadence (steps per minute), and bilateral step lengths (38-40). Walking speed (V) will be calculated using the formula: |
Baseline and immediately after intervention
|
|
Walking Speed
Time Frame: Baseline and immediately after intervention
|
Kinovea® software (version 0.8.15) is used to perform objective and quantitative kinematic and spatiotemporal gait analysis from video recordings. The software enables the analysis of parameters such as step length, stride length, base of support, step width, cadence, walking speed, and step time (37). In this study, gait will be recorded using a camera positioned in the sagittal plane while participants walk a distance of 3 meters. Colored markers will be placed on the right and left heels to facilitate identification in the video recordings. Several gait cycles will be captured and analyzed independently using Kinovea software to determine step length (distance between consecutive heel strikes of opposite limbs), stride length (distance between consecutive heel strikes of the same limb), cadence (steps per minute), and bilateral step lengths (38-40). Walking speed (V) will be calculated using the formula: |
Baseline and immediately after intervention
|
|
Modified Fatigue Impact Scale
Time Frame: Baseline and immediately after intervention
|
The Modified Fatigue Impact Scale (MFIS) is a 21-item questionnaire designed to assess the impact of fatigue on physical, cognitive, and psychosocial functioning (41).
Each item is scored on a 5-point Likert scale ranging from 0 (no problem) to 4 (severe problem).
The total score ranges from 0 to 84, with higher scores indicating greater fatigue severity.
Subscale scores for physical, cognitive, and psychosocial domains are calculated and summed to obtain the total score.
|
Baseline and immediately after intervention
|
|
The Four Square Step Test
Time Frame: Baseline and immediately after intervention
|
The Four Square Step Test evaluates the ability to change direction while stepping.
Participants begin in Square 1 (upper left) and follow a predefined stepping sequence clockwise (Squares 1-2-4-3) and then counterclockwise (Squares 3-4-2-1).
The physiotherapist demonstrates the test and allows practice trials if needed.
If the participant loses balance, touches the assistive device, or fails to complete the sequence, the test is repeated.
Two trials are recorded, and the best performance time is used for analysis.
Timing begins when the first foot contacts Square 2 and ends when both feet return to Square 1
|
Baseline and immediately after intervention
|
|
BICAMS Battery
Time Frame: Baseline and immediately after intervention
|
The BICAMS battery includes the Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-Second Edition (CVLT-II), and Brief Visuospatial Memory Test-Revised (BVMT-R).
The battery was recommended in 2012 for monitoring cognitive function in individuals with MS, and its Turkish validity and reliability were established in 2017
|
Baseline and immediately after intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Guzin Kaya Aytutuldu, Biruni University
Publications and helpful links
General Publications
- Conklyn D, Stough D, Novak E, Paczak S, Chemali K, Bethoux F. A home-based walking program using rhythmic auditory stimulation improves gait performance in patients with multiple sclerosis: a pilot study. Neurorehabil Neural Repair. 2010 Nov-Dec;24(9):835-42. doi: 10.1177/1545968310372139. Epub 2010 Jul 19.
- Ehde DM, Elzea JL, Verrall AM, Gibbons LE, Smith AE, Amtmann D. Efficacy of a Telephone-Delivered Self-Management Intervention for Persons With Multiple Sclerosis: A Randomized Controlled Trial With a One-Year Follow-Up. Arch Phys Med Rehabil. 2015 Nov;96(11):1945-58.e2. doi: 10.1016/j.apmr.2015.07.015. Epub 2015 Aug 6.
- Benedetti MG, Piperno R, Simoncini L, Bonato P, Tonini A, Giannini S. Gait abnormalities in minimally impaired multiple sclerosis patients. Mult Scler. 1999 Oct;5(5):363-8. doi: 10.1177/135245859900500510.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Biruni.U
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Breathing and General Mobility Exercises
-
Istanbul Medipol University HospitalCompletedMobility Limitation | ExercisesTurkey
-
University of ValenciaCompleted
-
Ankara Yildirim Beyazıt UniversityCompletedShoulder Pain | Diaphragm IssuesTurkey
-
Derya AzimCompletedStroke | Physiotherapy and RehabilitationTurkey
-
Uppsala UniversityThe Swedish Research Council; Örebro County CouncilCompleted
-
Federal University of BahiaCompletedParkinson Disease | DysphagiaBrazil
-
Riphah International UniversityCompleted
-
Ankara Yildirim Beyazıt UniversityNot yet recruitingSubacromial Pain SyndromeTurkey
-
Rawan Mohammed Khairy Mostafa ElsawyCairo UniversityRecruitingChild, Only | Pulmonary Function | Functional Capacity | Thalassemia Major | Incentive SpirometerEgypt